Kollmar, Otto

[["dc.bibliographiccitation.firstpage","2039"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical Oral Investigations"],["dc.bibliographiccitation.lastpage","2045"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Schmalz, Gerhard"],["dc.contributor.author","Meisel, Anja"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kauffels, Anne"],["dc.contributor.author","Slotta, Jan E."],["dc.contributor.author","Kottmann, Tanja"],["dc.contributor.author","Haak, Rainer"],["dc.contributor.author","Ziebolz, Dirk"],["dc.date.accessioned","2021-06-01T10:49:16Z"],["dc.date.available","2021-06-01T10:49:16Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00784-017-2298-5"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86222"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1436-3771"],["dc.relation.issn","1432-6981"],["dc.title","Oral health-related quality of life depending on dental and periodontal health in different patients before and after liver transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","392"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Hoffmann, Katrin"],["dc.contributor.author","Ganten, Tom M."],["dc.contributor.author","Gotthardtp, Daniel"],["dc.contributor.author","Radeleff, Boris"],["dc.contributor.author","Settmacher, Utz"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Nadalin, Silvio"],["dc.contributor.author","Karapanagiotou-Schenkel, Irini"],["dc.contributor.author","von Kalle, Christof"],["dc.contributor.author","Jaeger, Dirk"],["dc.contributor.author","Buechler, Markus W."],["dc.contributor.author","Schemmer, Peter"],["dc.date.accessioned","2018-11-07T09:57:18Z"],["dc.date.available","2018-11-07T09:57:18Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in the treated HCC nodule, however, the risk of tumour development in the untreated liver is increased by simultaneous release of neo-angiogenic factors. Due to its anti-angiogenic effects, Sorafenib delays the progression of HCC. Aim of this study was to determine whether combination of TACE and Sorafenib improves tumour control in HCC patients on waiting list for LT. Methods: Fifty patients were randomly assigned on a 1:1 ratio in double-blinded fashion at four centers in Germany and treated with TACE plus either Sorafenib (n = 24) or placebo (n = 26). The end of treatment was development of progressive disease according to mRECIST criteria or LT. The primary endpoint of the trial was the Time-to-Progression (TTP). Other efficacy endpoints were Tumour Response, Progression-free Survival (PFS), and Time-to-LT (TTLT). Results: The median time of treatment was 125 days with Sorafenib and 171 days with the placebo. Fourteen patients (seven from each group) developed tumour progression during the course of the study period. The Hazard Ratio of TTP was 1.106 (95% CI: 0.387, 3.162). The results of the Objective Response Rate, Disease Control Rate, PFS, and TTLT were comparable in both groups. The incidence of AEs was comparable in the placebo group (n = 23, 92%) and in the Sorafenib group (n = 23, 96%). Twelve patients (50%) on Sorafenib and four patients (16%) on placebo experienced severe treatment-related AEs. Conclusion: The TTP is similar after neo-adjuvant treatment with TACE and Sorafenib before LT compared to TACE and placebo. The Tumour Response, PFS, and TTLT were comparable. The safety profile of the Sorafenib group was similar to that of the placebo group."],["dc.description.sponsorship","Bayer Vital GmbH, Leverkusen, Germany"],["dc.identifier.doi","10.1186/s12885-015-1373-z"],["dc.identifier.isi","000355401800001"],["dc.identifier.pmid","25957784"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12352"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37126"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Ziemann, C."],["dc.contributor.author","Gittler, Anika"],["dc.contributor.author","Benz-Weisser, Anna"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:44:06Z"],["dc.date.available","2018-11-07T09:44:06Z"],["dc.date.issued","2014"],["dc.format.extent","49"],["dc.identifier.isi","000332306700162"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34323"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Locoregional application of temsirolimus is effective to inhibit tumor growth of CC531 colorectal liver metastases even after stimulation by hepatectomy or portal branch ligation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","376"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie"],["dc.bibliographiccitation.lastpage","381"],["dc.bibliographiccitation.volume","140"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Schilling, Martin Karl"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:53:47Z"],["dc.date.available","2018-11-07T09:53:47Z"],["dc.date.issued","2015"],["dc.description.abstract","Since September 1st, 2009, the most recent version of the German \"Betreuungsrechtsanderungsgesetz\" has been validated by the legislators. It precisely sets out how physicians and nursing staff have to deal with a written declaration of a patient's will. This new law focuses in a special way on advance directives, describes the precise rules for the authors of an advance directive and shows both its sphere of action and its limitations. This article aims to give an overview on the legal scope of advance directives, and to illustrate potential limitations and conflicts. Furthermore, it shows the commitments and rights of the medical team against the background of an existing advance directive."],["dc.identifier.doi","10.1055/s-0032-1328354"],["dc.identifier.isi","000359715500009"],["dc.identifier.pmid","23696206"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36398"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1438-9592"],["dc.relation.issn","0044-409X"],["dc.title","Advance Directives - Not a Lot of Margin for Error - The Surgeon's View of a Complex Medical-Legal Topic"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","25"],["dc.bibliographiccitation.issue","1-4"],["dc.bibliographiccitation.journal","European Surgical Research"],["dc.bibliographiccitation.lastpage","36"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Senger, Sebastian"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Schilling, Martin Karl"],["dc.contributor.author","Rupertus, Kathrin"],["dc.date.accessioned","2018-11-07T09:45:46Z"],["dc.date.available","2018-11-07T09:45:46Z"],["dc.date.issued","2014"],["dc.description.abstract","Purpose: Erythropoietin and its analogue darbepoetin (DPO)-alpha have been shown to improve liver function and regeneration after partial hepatectomy (Phx). However, previous experimental studies have also shown that DPO significantly enhances Phx-induced engraftment of colorectal liver metastases by increasing neovascularization and tumor cell proliferation. Therefore, the present study analyzed whether DPO affects engraftment and neovascularization of extrahepatic colorectal metastases after major hepatectomy. Methods: Green fluorescent protein-transfected CT26.WT colorectal cancer cells were implanted into dorsal skinfold chambers of syngeneic BALB/c mice. Animals received a single dose of DPO (10 mu g/kg body weight) at the day of tumor cell implantation (day 0). Phosphate-buffered saline-treated animals served as controls. To study whether the effect of DPO is influenced by Phx, additional animals with and without DPO treatment underwent 70% Phx at day 0. Tumor vascularization and growth as well as tumor cell migration, proliferation and apoptosis were studied repetitively over 14 days using intravital fluorescence microscopy, histology and immunohistochemistry. Results: In nonhepatectomized animals, DPO significantly accelerated tumor cell engraftment and slightly enhanced tumor neovascularization. Tumor cell migration and host tissue infiltration were not affected by DPO. In hepatectomized animals, DPO slightly enhanced tumor growth and significantly accelerated tumor neovascularization, but did not affect tumor cell migration and infiltration. Conclusion: The present study indicates that DPO accelerates extrahepatic engraftment of colorectal cancer cells, most probably by stimulating the process of neovascularization. (C) 2014 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000364944"],["dc.identifier.isi","000342748100003"],["dc.identifier.pmid","25012086"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34700"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1421-9921"],["dc.relation.issn","0014-312X"],["dc.title","Darbepoetin-alpha Accelerates Neovascularization and Engraftment of Extrahepatic Colorectal Metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Roller, Jonas"],["dc.contributor.author","Malter, Markus M."],["dc.contributor.author","Keller, Kira"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Glanemann, Matthias"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Sperling, Jens"],["dc.date.accessioned","2020-12-10T18:38:54Z"],["dc.date.available","2020-12-10T18:38:54Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s12885-019-6135-x"],["dc.identifier.eissn","1471-2407"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16951"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77472"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.format.extent","874"],["dc.identifier.isi","000338033304007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33231"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","713"],["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.lastpage","714"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Beck, J."],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.identifier.isi","000338033303192"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33230"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Potential of Graft-Derived Cell-Free DNA Quantification to Improve Outcomes With Marginal Donor Organs - Case Report of Successful Liver Transplantation of a HELLP Syndrome Donor."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]